Vitadio: Pioneering Digital Therapeutics for Type 2 Diabetes
Vitadio was born from a simple idea – bringing better health to people by connecting them with nutritionists and focusing on lifestyle intervention. However, co-founder Lenka and her team soon realized that their software alone had the potential to deliver clinical benefits. Originally focused on obesity and wellness, Vitadio’s mission evolved into addressing type 2 diabetes, a pressing healthcare challenge with a clearer path for integration into healthcare systems.
The journey from idea to fully-fledged digital therapeutic was anything but simple. Vitadio faced the complex task of navigating Europe’s healthcare regulations, particularly in Germany, where they sought reimbursement. Lenka describes the regulatory path as daunting: “There’s limited knowledge about certifying digital medical products. The regulatory landscape follows different timelines than software development, which can feel overwhelming.” Alongside this challenge, Vitadio invested heavily in clinical validation, recognising that real impact in the healthcare sector required rigorous evidence of efficacy. Building this clinical foundation became one of Vitadio’s competitive advantages, as they accumulated a level of peer-reviewed evidence unmatched by other digital solutions for diabetes in Europe.
To support their growth and navigate these complexities, Vitadio joined EIT Health’s start-up programmes. Initially invited to the Smart Ageing Bootcamp in Dublin, Lenka quickly recognised the value of EIT Health’s offerings. The bootcamp introduced them to diverse European healthcare systems, different business models, and reimbursement frameworks—key insights that shaped Vitadio’s decision to enter the German market. “The bootcamp was a turning point,” Lenka recalls, “It showed us different market perspectives and introduced us to Germany’s DIGA program, which shaped our entire approach.”
Later, Vitadio participated in another of EIT Health’s accelerator programme, which provided further funding and access to experts across Europe. This support was invaluable, especially as they worked towards permanent reimbursement in Germany. EIT Health’s programs also lent credibility to Vitadio, positioning the team as more than a typical startup. “EIT Health’s name gave us credibility,” Lenka explains, “When you reach out to stakeholders as part of their network, it’s not just four people in a garage – it’s a serious effort.”
Today, Vitadio is the only permanently reimbursed digital therapy for type 2 diabetes in Europe, recognised for its clinical effectiveness and patient-friendly design. As they expand their product line and reach into other European markets, Vitadio continues to advance digital health, providing accessible, evidence-based diabetes care for aging populations.
Vitadio’s Journey Highlights:
– From Obesity to Diabetes: Evolved from general wellness into a dedicated digital therapeutic for type 2 diabetes.
– Clinical Excellence: Developed an evidence-backed approach with multiple peer-reviewed studies, gaining competitive advantage.
– Navigating Regulations: Overcame regulatory hurdles with support from EIT Health, achieving permanent reimbursement in Germany.
– Expanding Impact: Looking to broaden both product portfolio and market reach to address more cardio-metabolic conditions.
Vitadio’s journey is a testament to the power of adaptability, strategic partnerships, and a deep commitment to healthcare innovation.